Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

被引:19
|
作者
Caslake, Muriel J. [1 ]
Packard, Chris J.
Robertson, Michele [2 ]
Cooney, Josephine
Nelson, Jeanenne J. [3 ]
Ford, Ian [2 ]
Gaw, Allan [4 ]
Jukema, J. Wouter [5 ]
Macfarlane, Peter W.
Stott, David J.
Shepherd, James
机构
[1] Univ Glasgow, Western Infirm Glasgow, Vasc Biochem Grp, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland
[2] Univ Glasgow, Robertson Ctr Biostat, Glasgow G11 6NT, Lanark, Scotland
[3] GlaxoSmithKline, Worldwide Epidemiol, Res Triangle Pk, NC USA
[4] NHS Greater Glasgow & Clyde, Glasgow Clin Res Facil, Glasgow, Lanark, Scotland
[5] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands
关键词
Lipoprotein-associated phospholipids A(2); Elderly; Prosper; Inflammatory markers; Coronary heart disease risk; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; MIDDLE-AGED MEN; ATHEROSCLEROSIS RISK; ISCHEMIC-STROKE; PREDICTION; EVENTS; MARKERS; WOMEN;
D O I
10.1016/j.atherosclerosis.2009.10.041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an inflammatory biomarker that circulates mainly bound to LDL. We evaluated the association of Lp-PLA(2) with vascular events in the elderly where the importance of LDL is diminished as a risk factor for coronary disease. Methods: Mass and activity of Lp-PLA(2) were related to risk over 3.2 years for vascular events (definite or suspected death from CHD, non-fatal MI, fatal or non-fatal stroke) in the 2804 men and 3000 women age 70-82 years in the Prospective Study of Pravastatin in the Elderly (PROSPER). Results: Lp-PLA(2) showed a moderate, positive association with risk of a vascular event with hazard ratios of 1.25 (confidence interval (CI) 1.02-1.54) for mass and 1.39 (CI 1.14-1.70) for activity for top versus bottom quartile. Risk associations were attenuated when classical risk factors, lipids and in. ammatory markers - C-reactive protein and white cell count - were included in the models. Lp-PLA(2) was unrelated to stroke risk. Inclusion of all three in. ammatory markers in multivariate models negated the association of HDL cholesterol with risk (hazard ratio 0.98; CI 0.88-1.10) and increased prediction of coronary events; the C statistic rose from 63.2% to 64.4% (P < 0.001). Conclusion: In elderly people Lp-PLA(2), alongside other inflammatory indices, is a potential biomarker for vascular events, particularly CHD. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:28 / 34
页数:7
相关论文
共 50 条
  • [41] Lipoprotein-associated phospholipase A2:: a novel marker of cardiovascular risk and potential therapeutic target
    Macphee, C
    Benson, GM
    Shi, Y
    Zalewski, A
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (06) : 671 - 679
  • [42] Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker
    Corson, Marshall A.
    Jones, Peter H.
    Davidson, Michael H.
    AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (12A): : 41F - 50F
  • [43] Risk of stroke and elevated levels of lipoprotein-associated phospholipase A2
    Alberts, Mark J.
    Ballantyne, Christie
    Elkind, Mitchell S.
    STROKE, 2008, 39 (02) : 642 - 642
  • [44] Lipoprotein-Associated Phospholipase A2 Activity and Risk of Recurrent Stroke
    Elkind, Mitchell S. V.
    Tai, Wanling
    Coates, Kristen
    Paik, Myunghee C.
    Sacco, Ralph L.
    CEREBROVASCULAR DISEASES, 2009, 27 (01) : 42 - 50
  • [45] Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke
    Elkind, Mitchell S.
    Tai, Wanling
    Coates, Kristen
    Paik, Myunghee
    Sacco, Ralph L.
    STROKE, 2007, 38 (02) : 528 - 528
  • [46] Lipoprotein-associated phospholipase A2: Risk marker or target of therapy?
    Ballantyne C.M.
    Current Cardiovascular Risk Reports, 2007, 1 (1) : 66 - 71
  • [47] Lipoprotein-associated phospholipase A2 and venous thromboembolism: A prospective study
    Folsom, Aaron R.
    Lutsey, Pamela L.
    Roetker, Nicholas S.
    Ballantyne, Christie M.
    Hoogeveen, Ron C.
    Rosamond, Wayne D.
    Cushman, Mary
    THROMBOSIS RESEARCH, 2013, 132 (01) : 44 - 46
  • [48] The relationship between lipoprotein-associated phospholipase A2 with cardiovascular risk factors in testosterone deficiency
    Kelesoglu, Mustafa
    Kizilay, Fuat
    Barutcuoglu, Burcu
    Basol, Gunes
    Sarac, Fulden
    Mutaf, Isil
    Semerci, Bulent
    TURKISH JOURNAL OF UROLOGY, 2018, 44 (02): : 103 - 108
  • [49] Lipoprotein-associated phospholipase A2 is associated with risk of coronary heart disease and stroke. The Rotterdam study
    Oei, HHS
    Van der Meer, IM
    Hofman, A
    Breteler, MMB
    Witteman, JCM
    EUROPEAN HEART JOURNAL, 2004, 25 : 234 - 234
  • [50] Lipoprotein-Associated Phospholipase A2 and Risk of Congestive Heart Failure in Older Adults The Cardiovascular Health Study
    Suzuki, Takeki
    Solomon, Cam
    Jenny, Nancy Swords
    Tracy, Russell
    Nelson, Jeanenne J.
    Psaty, Bruce M.
    Furberg, Curt
    Cushman, Mary
    CIRCULATION-HEART FAILURE, 2009, 2 (05) : 429 - 436